Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 3251 of 6351
-
Could a chair improve Men's sexual function? new trial investigates
Symptom relief Recruiting nowWe will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, w…
Sponsor: Corewell Health East • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Light-Activated gel shows promise for psoriasis in early trial
Disease control CompletedTo evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Phase 2 • Sponsor: Soligenix • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental cocktail aims to outsmart resistant myeloma
Disease control OngoingThe main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when giv…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Head-to-Head: which drug lifts bipolar depression faster?
Symptom relief Recruiting nowThe goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depres…
Phase 4 • Sponsor: Aalborg University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Nerve-Zapping earbuds could help anorexia patients eat without fear
Symptom relief Recruiting nowThis project includes a 4-week randomized trial comparing pre-meal vagal nerve stimulation (taVNS) to pre-meal sham stimulation. The aims will assess if taVNS results in greater satisfaction, greater calorie consumption, less self-reported fullness, decrease in eating disorder sy…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New study aims to ease Radiation's burning side effect
Symptom relief CompletedThe purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Online buddy training may keep Ex-Smokers from relapsing
Disease control OngoingThe purpose of this study is to assess the effect of the Helpers Stay Quit training on abstinence over time of newly abstinent smokers, and on the interactions they have with their personal network related to smoking and smoking cessation.
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for tough blood cancers? early trial tests LYT-200
Disease control CompletedA Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
Phase 1 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental cell therapy targets stubborn leukemia in early trial
Disease control Stopped earlyThis is a prospective, single-arm, open-label, single dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-AMDR cells in subjects with relapsed/refractory Acute Myeloid Leukemia who received adequate standard therapy.
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug shows promise in early trial for rare blood disorder
Disease control CompletedThe purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Phase 1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can bright light ease Parkinson's sleep and mood troubles?
Symptom relief CompletedThis is a randomized placebo- and active-controlled trial for assessing the efficacy of bright light therapy for sleep and mood symptoms in patients with Parkinson's disease
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Simple brain game eases haunting memories for COVID-19 frontline workers
Symptom relief CompletedFrontline healthcare staff are frequently exposed to traumatic events at work (e.g., witnessing patients die), amplified by the COVID-19 pandemic. A significant proportion experience intrusive memories of these events that pop suddenly into mind: they can disrupt functioning and …
Sponsor: P1vital Products Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New eye drug shows promise for Diabetes-Related vision loss
Disease control OngoingThis study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 …
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Balloon catheter aims to supercharge blood flow to heart and brain during arrest
Disease control CompletedThe NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating…
Sponsor: neurescue • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Stroke survivors may regain arm function with intensive therapy
Symptom relief Recruiting nowConstraint-Induced Therapy (CI Therapy) is a behavioral approach to neurorehabilitation and consists of multi-components that have been applied in a systematic method to improve the use of the limb or function addressed in the intensive treatment. CI Therapy for the more-affected…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Diabetes drug shows promise for quitting smoking without weight gain
Symptom relief CompletedThe purpose of this study is to determine if exenatide improves end-of-treatment smoking abstinence rates and to determine if exenatide mitigates post-cessation weight gain.
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control CompletedThis is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into …
Phase 1 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New program aims to boost cancer patients' quality of life with daily emails and biofeedback
Symptom relief CompletedThe Cancer Patient Empowerment Program is a comprehensive health promotion program aiming to improve the quality of life as well as both physical and mental health in cancer patients and survivors. The program includes daily email communications over 6 months that encourage stren…
Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Could aspirin and ketamine be the next depression breakthrough?
Symptom relief CompletedThe purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
Phase 4 • Sponsor: Theresa Jacob, PhD, MPH • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug WTX-330 shows promise in early human trial
Disease control CompletedA first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Phase 1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC